Evidence map›Paper›PMID 32789582›Full record

ArticleJournal of molecular modeling2020

Computational analysis of complement inhibitor compstatin using molecular dynamics.

Didier Devaurs, Dinler A Antunes, Lydia E Kavraki

Open access · bronzeAbstract read
In one paragraph

Article in Journal of molecular modeling, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Didier DevaursUniversity of Grenoble Alpes, CNRS, Inria, Grenoble INP, LJK, 38000, Grenoble, France.ORCID http://orcid.org/0000-0002-3415-9816
Dinler A AntunesDepartment of Computer Science, Rice University, 6100 Main St, Houston, TX, 77005, USA.
Lydia E KavrakiDepartment of Computer Science, Rice University, 6100 Main St, Houston, TX, 77005, USA. kavraki@rice.edu.
Rice University · USInstitut polytechnique de Grenoble · FR

Funding

Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
National Science Foundation CCF 1423304NIGMS NIH HHS P41 GM103311
6 · The paper itself

Abstract

The complement system plays a major role in human immunity, but its abnormal activation can have severe pathological impacts. By mimicking a natural mechanism of complement regulation, the small peptide compstatin has proven to be a very promising complement inhibitor. Over the years, several compstatin analogs have been created, with improved inhibitory potency. A recent analog is being developed as a candidate drug against several pathological conditions, including COVID-19. However, the reasons behind its higher potency and increased binding affinity to complement proteins are not fully clear. This computational study highlights the mechanistic properties of several compstatin analogs, thus complementing previous experimental studies. We perform molecular dynamics simulations involving six analogs alone in solution and two complexes with compstatin bound to complement component 3. These simulations reveal that all the analogs we consider, except the original compstatin, naturally adopt a pre-bound conformation in solution. Interestingly, this set of analogs adopting a pre-bound conformation includes analogs that were not known to benefit from this behavior. We also show that the most recent compstatin analog (among those we consider) forms a stronger hydrogen bond network with its complement receptor than an earlier analog.

Indexed as

Antiviral AgentsComplement C3Coronavirus InfectionsCOVID-19HumansHydrogen BondingMolecular Dynamics SimulationPandemicsPeptides, CyclicPneumonia, ViralStructure-Activity RelationshipAntiviral AgentsC3 protein, humanComplement C3compstatinPeptides, CyclicComplement inhibitionComplement systemCompstatinMolecular dynamics

Identifiers

PMID32789582
PMCPMC8851517
OpenAlexW3048799182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.